Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (17)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Management of multiple myeloma-related renal impairment : recommendations from the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2023

von Dimopoulos, M. | Merlini, G. | Bridoux, F. | +25

3

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

enthalten in: Haematologica | 2022

von Fokkema, C. | Moreau, P. | Van der Holt, B. | +17

4

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Sonneveld, P. | Dimopoulos, M. | Beksac, M. | +37

5

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Hulin, C. | Perrot, A. | +49

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34545220

6

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

enthalten in: Haematologica | 2021

von Hulin, C. | Offner, F. | Moreau, P. | +20

7

Expert review on soft-tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations

enthalten in: British journal of haematology | 2021

von Rosiñol, L. | Beksac, M. | Zamagni, E. | +35

8

Sequencing multiple myeloma therapies with and after antibody therapies

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von van de Donk, N.

9

Should all newly diagnosed MM patients receive CD38 antibody-based treatment?

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von Korst, C. | van de Donk, N.

10

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

enthalten in: Haematologica | 2020

von Zweegman, S. | Stege, C. | Haukas, E. | +23